Test Details: The KRAS mutation, which has been associated with several human cancers including lung adenocarcinomas, pancreatic cancers, gastric cancers, biliary cancers and colorectal cancers, is often an early event in tumorigenesis. The mutations of clinical significance are commonly observed in Exon 2 codons 12/ 13, Exon 3-codon 61 and Exon 4-codon 117/146 and are frequent in colorectal carcinomas. The impact of KRAS mutation on the efficacy of therapies that target the epidermal growth factor (EGFR) is aimed at identifying the best possible treatments.